ASLAN Pharmaceuticals Ltd (ASLN) Stock Price, Quote, News and Overview
NASDAQ:ASLN - Nasdaq - US04522R2004 - ADR - Currency: USD
ASLN Quote, Performance and Key Statistics
0.6
-0.1 (-14.27%)
The current stock price of ASLN is 0.6 USD. In the past month the price decreased by -75.97%. In the past year, price decreased by -97.26%.
ASLN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About ASLN
Company Profile
Aslan Pharmaceuticals Ltd is a SG-based company operating in Biotechnology industry. ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The firm's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. The company is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The firm is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The firm is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Company Info
ASLAN Pharmaceuticals Ltd
83 Clemenceau Avenue, #12-03 UE Square
Singapore 239920 SG
CEO: Carl Firth
Employees: 34
Company Website: http://aslanpharma.com/zh/
Phone: 6562224235
ASLAN Pharmaceuticals Ltd / ASLN FAQ
What is the stock price of ASLAN Pharmaceuticals Ltd today?
The current stock price of ASLN is 0.6 USD. The price decreased by -14.27% in the last trading session.
What is the ticker symbol for ASLAN Pharmaceuticals Ltd stock?
The exchange symbol of ASLAN Pharmaceuticals Ltd is ASLN and it is listed on the Nasdaq exchange.
On which exchange is ASLN stock listed?
ASLN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ASLAN Pharmaceuticals Ltd stock?
8 analysts have analysed ASLN and the average price target is 77.52 USD. This implies a price increase of 12820% is expected in the next year compared to the current price of 0.6. Check the ASLAN Pharmaceuticals Ltd stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASLAN Pharmaceuticals Ltd worth?
ASLAN Pharmaceuticals Ltd (ASLN) has a market capitalization of 1.70M USD. This makes ASLN a Nano Cap stock.
How many employees does ASLAN Pharmaceuticals Ltd have?
ASLAN Pharmaceuticals Ltd (ASLN) currently has 34 employees.
Is ASLAN Pharmaceuticals Ltd (ASLN) expected to grow?
The Revenue of ASLAN Pharmaceuticals Ltd (ASLN) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ASLN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ASLAN Pharmaceuticals Ltd (ASLN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ASLN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ASLN, evaluating the profitability, health, valuation and growth aspects
- ASLAN Pharmaceuticals Ltd (ASLN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASLAN Pharmaceuticals Ltd (ASLN) Sales and EPS estimates to see what analysts future expectations are.
- ASLAN Pharmaceuticals Ltd (ASLN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASLAN Pharmaceuticals Ltd (ASLN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASLAN Pharmaceuticals Ltd (ASLN) Stock Chart to make your own analysis
- ASLAN Pharmaceuticals Ltd (ASLN) Latest news and press-releases to stay up to date.
Does ASLAN Pharmaceuticals Ltd (ASLN) stock pay dividends?
ASLN does not pay a dividend.
When does ASLAN Pharmaceuticals Ltd (ASLN) report earnings?
ASLAN Pharmaceuticals Ltd (ASLN) will report earnings on 2024-08-09, before the market open.
What is the Price/Earnings (PE) ratio of ASLAN Pharmaceuticals Ltd (ASLN)?
ASLAN Pharmaceuticals Ltd (ASLN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.15).
ASLN Technical Analysis
ASLN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ASLN. ASLN may be in some trouble as it scores bad on both profitability and health.
ASLN Financial Highlights
Over the last trailing twelve months ASLN reported a non-GAAP Earnings per Share(EPS) of -11.15. The EPS decreased by -173.28% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -93.07% | ||
| ROE | -806.53% | ||
| Debt/Equity | 3.84 |
ASLN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to ASLN. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 58.45% and a revenue growth -100% for ASLN